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ess: M.Duiverman@BeaSummary We performed a retrospective analysis to the effects of negative
pressure ventilation (NPV), tracheal intermittent positive pressure ventilation
(TIPPV), and nasal intermittent positive pressure ventilation (NIPPV, volume or
pressure-controlled ventilatory mode), in 114 patients with restrictive ventilatory
disorders instituted in our hospital from 1956 until 2005. The patients were assigned
on ‘‘ad hoc’’ basis to NPV, TIPPV, or NIPPV.
All patients were subdivided in an idiopathic kyphoscoliosis group (IK, n ¼ 64), a
post-poliomyelitis syndrome group (PP, n ¼ 30), or a miscellaneous group (M,
n ¼ 20). The patients in the PP group had higher survival rates compared to the IK
patients (Po0:05), while the M patients had the lowest survival rates (Po0:01). Both
NPV (Po0:01) and TIPPV (Po0:05) lead to a decrease in PaCO2 after 9 months
compared to baseline. This decrease in PaCO2 was still present after 5 years NPV
(Po0:001) and TIPPV (Po0:05). NIPPV lead to an improvement in pulmonary
function (Po0:05) and arterial blood gases (Po0:001) after 9 months compared to
baseline. After 5 years NIPPV, the arterial blood gases were still significantly
improved compared to baseline (Po0:01). Both volume-controlled and pressure-
controlled ventilation improved pulmonary function and arterial blood gases.
Conclusion: Long-term home mechanical ventilatory support by both NPV and
positive pressure ventilation is effective in patients with IK, PP syndrome, and a M
group, even after a period of 5 years.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
3613200; fax: +31 50 3613900.
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HMV support in patients with restrictive ventilatory disorders 57Introduction
Restrictive ventilatory disorders are characterized
by a reduced chest wall compliance and mechanical
disadvantage of the respiratory muscles leading to
a decrease in respiratory function and an increase
in the work of breathing. Therefore, patients with
restrictive ventilatory disorders will adopt a pat-
tern of rapid, shallow breathing, which may result
in chronic alveolar hypoventilation. During sleep,
there is a progressive fall in minute ventilation
exaggerating the hypoventilation. As a conse-
quence, these patients develop hypercapnia, firstly
during sleep, and finally in wakefulness.1 Even-
tually, respiratory failure may occur, which makes
chronic ventilatory support necessary.2
Home mechanical ventilation (HMV) has been
used for more than 60 years now in a variety of
disorders. Several methods have been used: firstly
only negative pressure ventilation (NPV) was avail-
able, later on tracheal intermittent positive pres-
sure ventilation (TIPPV) appeared, and finally nasal
intermittent positive pressure ventilation (NIPPV)
became available.
NPV devices are cumbersome to use and may
lead to insufficient ventilation due to an inade-
quate covering of the chest wall surface and the
abdomen. In our hospital we solved this problem by
using a specially designed tailor-made shell.3
Despite the disadvantages of NPV, it has shown
beneficial effects in patients with a variety of
pulmonary disorders, including patients with re-
strictive ventilatory disorders.4–8
TIPPV has been shown to be effective in patients
with restrictive ventilatory disorders.9,10 Although
the use of TIPPV is limited by drawbacks such as
disfigurement, difficulties associated with phona-
tion, risk of infection, and the burden of tracheost-
omy care, this therapy is nowadays still prescribed
to obtain adequate ventilatory support.
NIPPV is nowadays the most frequently used
mode of ventilatory support in patients with
restrictive ventilatory disorders. Several studies
have shown the benefits of NIPPV in terms of
improvement in daytime arterial blood gas ten-
sions, relief of nocturnal hypoventilation and its
symptoms, improvement of health-related quality
of life, and improved survival.11–28 At the introduc-
tion of NIPPV, only volume-controlled ventilators
were available. Later, pressure-controlled and
bilevel pressure-controlled ventilation became
available as well. Only a few studies have com-
pared the effects of volume-controlled vs. pres-
sure-controlled ventilation.19,29,30
However, a number of issues are remarkable from
the above-mentioned studies. Firstly, many of themonly monitored the effects of non-invasive ventila-
tory support, while invasive ventilation is still being
used in a considerable number of patients. Sec-
ondly, most studies assessed the effect of ventila-
tory support for a short period. Finally, patients
with a variety of different disorders were placed
and analyzed in the same group to increase the
number of patients in the study groups.
In our hospital we have been using HMV since
1956 in a variety of disorders. For this study, we
selected the patients with kyphoscoliosis, post-
poliomyelitis (PP) syndrome, and other restrictive
ventilatory disorders for analysis of the effects of
HMV, as we have been able to build up long-term
experience with HMV in a large number of patients
with restrictive ventilatory disorders.
Therefore, the aim of the study was: (a) to
describe the development of HMV in our hospital,
and (b) to assess the effects of NPV, TIPPV, and
NIPPV on pulmonary function, arterial blood gas
tensions, and survival and in patients with kyphos-
coliosis, post-poliomyelitis syndrome and miscella-
neous restrictive ventilatory disorders. Therefore
we set up a retrospective analysis including all 114
patients with restrictive ventilatory disorders who
received ventilatory support in our hospital from
1956 until 2005.Methods
Subjects
Data were collected from all patients who received
HMV initiated at our department of HMV from 1956
until 2005. From this population we selected
patients with idiopathic kyphoscoliosis (IK), PP
syndrome and other restrictive ventilatory disor-
ders for analysis of the effects of HMV.
Ventilatory equipment and monitoring
Patients were ventilated by NPV, TIPPV, or NIPPV.
NPV was delivered by means of a chest respirator
with tailor-made shell.3 TIPPV was delivered by
means of volume or pressure ventilation. NIPPV was
delivered via nasal or full face mask, either by a
volume-controlled ventilator (Monnal D, Taema,
Antony Cedex, France; Lifecare PLV 100, Respiro-
nics, Murrysvile, USA; Breas PV 501, Breas Medical,
Mo¨lndal, Sweden), or a pressure-controlled
ventilator (bilevel pressure (BilevelPAP; Puritan
Bennet PB 335, Respironics, Murrysville, USA;
Respironics Synchrony, Respironics, Murrysville,
USA) or pressure-controlled (PCV; Airox VP 2000,
Beaumont, Migennes, France; Breas 401, Breas
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have the choice between volume-controlled or
pressure-controlled ventilators, in the past the
decision to implement a particular mode of
ventilation was dependent on the availability of
the ventilator in the market at the moment
patients were instituted.
All patients were instituted on ventilatory support
in the hospital. The indication for chronic ventila-
tory support was either chronic stable or progres-
sively deteriorating respiratory failure unresponsive
to other treatment options, both in combination
with symptoms such as increasing shortness of
breath on exertion, tiredness, and sleepiness.
Ventilator settings were determined at baseline
and adjusted depending on arterial blood gas
tensions. Before 1990, we measured arterial blood
gas tensions at rest during the day. Since 1990, we
performed an arterial blood gas registration in the
hospital during the night, initially without the
ventilator, and after the patients were able to
tolerate the ventilation for at least 6 h a night, with
the ventilator. Thereafter they were discharged
and followed at the outpatient clinic. After 2
months we performed another overnight arterial
blood gas registration while on the ventilator and
adjusted ventilator settings as necessary. Further-
more, the patients were monitored every 6 months,
including pulmonary function tests, daytime arter-
ial blood gas levels (ABG), and end-tidal CO2
measurements.
Supplemental oxygen was provided in patients in
whom arterial oxygen saturation remained low
(saturationo90%) despite optimal ventilator settings.
Data collection and analysis
We collected the following data: birth date, sex,
primary, and secondary diagnoses, indication for
initiating ventilatory support, date of starting and
ending ventilatory support, mode of ventilatory
support, oxygen need, and prescribed hours of
ventilatory support. Furthermore, we collected
data on pulmonary function, nocturnal and daytime
arterial blood gas analysis, and dependency in
activities of daily living (ADL) just before ventila-
tory support was initiated (baseline) and after 9
months, 112 years, 3 years, and then every 2 years
after initiating ventilatory support. Arterial blood
gas tensions were obtained while the patients were
breathing room air without ventilation.
Statistical analysis
Survival rates were calculated and compared
between the three diagnostic groups by using themethod of Kaplan–Meier and log rank tests.
Differences in the age at start between the
diagnostic groups (IK, PP, and M) were assessed by
a Kruskal Wallis test; differences in baseline
arterial blood gases and pulmonary function were
assessed by one-way analysis of variance.
We compared baseline arterial blood gases and
pulmonary function with the values obtained after
9 months (short-term effects) and to those after 5
years (the long-term effects) by multiple linear
regression of repeated measurements. Patients
who dropped out and patients from whom only
incomplete data could be collected were excluded
from these analyses.
Differences in baseline parameters between
patients ventilated by volume-controlled and pres-
sure-controlled NIPPV were assessed by Wilcoxon
sign rank tests. In the patients receiving volume-
controlled and pressure-controlled ventilation, we
compared baseline arterial blood gases and pul-
monary function with the values obtained after 9
months by Mann–Whitney U tests.Results
HMV at the University Medical Center
Groningen
From 1956 until January 1, 2005 we instituted 433
patients with a wide variety of disorders on HMV at
our hospital. We instituted patients with restrictive
ventilatory disorders (IK, PP complicated by ky-
phoscoliosis, post-tuberculosis); pure neuromuscu-
lar disorders (morbus Duchenne, amylotrofic lateral
sclerosis); pulmonary disorders (COPD patients,
cystic fibrosis patients); and patients with an
obstructive sleep apnea syndrome (OSAS) or obesity
hypoventilation syndrome (OHS). The treatment
prevalence of HMV in region of the HMV Center
Groningen was 5/100.000 on January 1, 2000 and
8.5/100.000 on January 1, 2005. This increase is
mainly caused by a more than fivefold increase in
the number of patients with ALS (2000; 6 active
users; 2005: 41 active users) and a more than
twofold increase in the number of patients with
OSAS or OHS (2000: 20; 2005: 44) (Fig. 1).
Characterization of the study subjects
We selected the patients with IK, the PP syndrome,
and other restrictive ventilatory disorders for
analysis of the effects of HMV. We subdivided these
patients in three groups according to their primary
diagnosis. The first group included 64 patients (25
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Figure 1 Annual number of patients with pulmonary disorders (pulmonary), restrictive ventilatory disorders
(restrictive), neuromuscular disorders (neuromuscular), and patients with the obstructive sleep apnea syndrome or
obesity hypoventilation syndrome (OSAS/OHS) subdivided into ‘‘already active users’’ (solid area) and ‘‘new users’’
(hatched area) of home mechanical ventilation (HMV) at the University Medical Center Groningen from 1980 until
January 1, 2005.
Table 1 Number of patients and baseline characteristics all patients per diagnostic group.
Diagnosis Number
(n)
Proportion
of acute
patients (%)
Age at start
(years)
FEV1 (L) VC (L) PaO2 (kPa) PaCO2 (kPa)
IK 64 39 56 (13.4) 0.77 (0.27) 1.10 (0.44) 7.44 (2.04) 7.77 (1.72)
PP 30 43 50 (15.8) 0.76 (0.35) 1.16 (0.61) 8.33 (1.56) 7.33 (1.34)
M 20 50 64y (10.2) 0.64 (0.15) 1.09 (0.43) 8.88z (1.81) 8.01 (2.19)
Values are expressed as mean (SD).
Note: VC: vital capacity; FEV1: forced expiratory volume in 1 s; PaO2: arterial oxygen pressure; PaCO2: arterial carbon dioxide
pressure.
M higher than IK (Po0:001).
yM higher than IK (Po0:05) and PP (Po0:01).
zM higher than IK (Po0:05).
HMV support in patients with restrictive ventilatory disorders 59men, 39 women) with IK. The second group
included 30 patients (15 men, 15 women) with
the PP syndrome. A third group included 20
patients with a miscellaneous restrictive ventila-
tory disorder. This group consisted of 12 patients (3
men, 9 women) who underwent a thoracoplasty
and/or (partial) lung resection for tuberculosis
(performed between 1939 and 1953), 5 patients
(3 men, 2 women) who experienced spondylitis
tuberculosa, 2 women with bronchiectasis (one of
them underwent a thoracoplasty in 1939), and 1
women with atelectase as a result of radiotherapy
for lung metastases. This group was called the
miscellaneous (M) group. Baseline characteristics of
the three diagnostic groups are shown in Table 1.
A total of 48 patients started ventilatory support
because of acute on chronic respiratory failure
(acute patients). For the other patients, ventila-
tory support was initiated non-emergently because
of chronic ventilatory failure with symptoms like
shortness of breath on exertion, tiredness, sleepi-ness, and morning headache (chronic patients). The
proportion of patients instituted acutely was higher
in the M group than in the IK group. At baseline, the
chronic patients had a significantly higher vital
capacity (VC; Po0:05), higher daytime PaO2
(Po0:003), and lower daytime PaCO2 (Po0:001)
compared to the acute patients.Survival and causes of death in three
different groups of patients
Figure 2 shows the cumulative survival of patients
from the three diagnostic groups receiving ventila-
tory support. The PP patients had higher survival
rates than the IK patients (Po0:05). The M patients
group experienced the lowest survival rates
(Po0:01) of all groups.
Of the 64 IK patients, 40 patients were still
being ventilated at our hospital at the time of
the analysis with a median duration 4.5 years
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Figure 2 Cumulative survival of idiopathic kyphoscoliosis patients, post-poliomyelitis patients, and patients with
miscellaneous restrictive ventilatory disorders, treated by home mechanical ventilation (HMV).
M.L. Duiverman et al.60(interquartile range 5.4). Twenty IK patients had
died after a median duration of 6.3 years HMV
(interquartile range 6.6); 11 patients died from
respiratory failure, 1 patient died from esophageal
cancer, 1 patient died from a malignant sarcoma, 1
patient got a fatal accident, and 6 patients died
from unknown causes. Furthermore, 3 IK patients
were lost from follow-up and 1 patient decided to
end the HMV after 1 month because of coping
problems. We found no significant differences in
age at start of ventilation, baseline pulmonary
function and arterial blood gas tensions between
the IK patients who had died and the IK patients
who were still alive at the time of the analysis.
However, the IK patients who had died had more
frequently been ventilated by TIPPV (25%) or NPV
(30%) compared to the IK patients who were
still alive at the time of the analysis (TIPPV: 7.5%,
NPV: 5%).
Of the 30 PP patients, 21 patients were still being
ventilated at the time of the analysis after a
median duration of 11.3 years (interquartile range
11.0). Nine PP patients had died after a median
duration of 10.3 years ventilatory support (inter-
quartile range 20.8); 4 patients died from respira-
tory failure, 2 patients died after surgery for a hip
fracture, 1 patient died from a cerebral hemorra-
ghea, and in 2 patients died from unknown causes.
We found no significant differences in age at the
start of ventilation, pulmonary function, arterialblood gas tensions, or type of ventilatory support at
baseline between the PP patients who had died and
the PP patients who were still alive at the time of
the analysis.
Of the 20 M patients, 5 patients were still being
ventilated at the time of the analysis after a
median duration of 5.1 years HMV (interquartile
range 3.4). Eleven M patients had died after a
median duration of 4.7 years HMV (interquartile
range 5.5); 3 M patients died from respiratory
failure, one patient died from a heart attack, 2
patients died after they became severely depressed
and quitted the assisted ventilation voluntarily, and
4 patients died from unknown causes. Furthermore,
3 M patients ended the ventilatory support (2 NIPPV
ventilated patients, 1 NPV ventilated patient)
because of coping problems after a median dura-
tion of 14 months ventilatory support (interquartile
range 40), and 1 patient was lost from follow-up.
We found no significant differences in age at start
of ventilation, pulmonary function, and arterial
blood gas tensions at baseline between the M
patients who had died, the M patients who were
still alive and the M patients who had stopped
because of coping problems. The M patients who
were still being ventilated at the time of the
analysis were all instituted non-emergently. In
contrast, the M patients who had died were more
frequently instituted acutely (9 patients instituted
acutely, 2 patients non-emergently).
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HMV support in patients with restrictive ventilatory disorders 61At baseline, a significantly higher proportion of IK
patients (73%) compared to the PP patients (47%)
and M patients (40%) was independent in ADL
(Po0:01). After 5 years HMV, significantly less IK
patients were ADL independent (54%) compared to
baseline. In the PP group the proportion of ADL
independent patients was not changed (47%) after 5
years HMV compared to baseline. In the M group
only 25% of the M patients was independent in ADL
after 5 years HMV compared to baseline (not
significant).Different types of ventilatory support
NPV
Twenty patients received NPV (9 IK patients, 8 PP
patients, 3 M patients). Sixteen patients were
ventilated with NPV for at least 5 years (80%).
NPV significantly improved PaCO2 after 9 months
and even after 5 years HMV (Table 2).
Only 1 IK patient and 1 PP patient changed from
NPV to TIPPV after 30 and 279 months, respectively.
One PP patient received 48 months cuirass followed
by 32 months NIPPV before he eventually switched
to TIPPV. The reason for switching to invasive
ventilatory support was deterioration into respira-
tory failure in all three patients. We found no
significant differences in baseline lung function
parameters and baseline daytime or overnight
arterial blood gas values between the patientsTable 2 Long-term changes in pulmonary function and ar
or NIPPV.
Ventilatory mode Baseline
NPV
FEV1 (n ¼ 7) 0.78 (0.49)
VC (n ¼ 7) 1.06 (0.66)
PaO2 (n ¼ 9) 6.97 (1.98)
PaCO2 (n ¼ 9) 8.58 (1.08)
TIPPV
FEV1 (n ¼ 4) 0.69 (0.18)
VC (n ¼ 5) 0.95 (0.36)
PaO2 (n ¼ 4) 6.89 (1.63)
PaCO2 (n ¼ 6) 9.71 (1.97)
NIPPV
FEV1 (n ¼ 27) 0.81 (0.28)
VC (n ¼ 29) 1.29 (0.58)
PaO2 (n ¼ 22) 7.86 (1.95)
PaCO2 (n ¼ 29) 7.46 (1.37)
Values are expressed as mean (SD).
Note: VC: vital capacity; FEV1: forced expiratory volume in 1 s; P
pressure.
*Po0:05 (compared to baseline); **Po0:01 (compared to baselinwho switched to TIPPV and the patients who
remained receiving ventilatory support by NPV.
TIPPV
Sixteen patients received TIPPV (9 IK patients, 4 PP
patients, 3 M patients). Eleven patients were
ventilated by TIPPV for at least 5 years (69%).
TIPPV improved PaCO2 after 9 months compared to
baseline, and this effect was still evident after 5
years (Table 2).
Two patients were instituted on TIPPV because of
chronic respiratory failure. One of those patients
got TIPPV in 1975 while he already received a
tracheostoma in 1968 for reducing dead space area
of the lungs, while in the other patient TIPPV was
used after NIPPV failed because of severe apneas
during NIPPV. Fourteen patients were instituted on
TIPPV after a period of severe acute respiratory
failure. This group consisted of 6 patients in whom
NIPPV was tried but failed repeatedly because no
improvement in gas exchange could be obtained or
because of severe sputum clearance problems, 4
patients who were set on TIPPV directly after a
period of intubation because of expected weaning
problems, 2 patients instituted on TIPPV before
NIPPV was available, and 2 patients who were
already tracheostomized in another hospital.
Later on, 3 patients changed from TIPPV to NIPPV
(1 patient from the IK group after 4 months (in
2000) and 2 patients from the PP group after 9
months (in 1993) and 52 months respectively (interial blood gases in patients ventilated by NPV, TIPPV
9 months 5 years
0.96 (0.46) 0.93 (0.37)
1.16 (0.68) 1.23 (0.55)
8.79 (1.82) 8.26 (1.76)
6.54 (0.88)** 6.52 (0.69)***
0.74 (0.21) 0.70 (0.24)
1.08 (0.32) 1.10 (0.43)
9.14 (1.73) 9.36 (1.86)
5.85 (0.76)* 6.00 (0.53)*
0.91 (0.31)* 0.87 (0.27)
1.42 (0.63)* 1.39 (0.64)
9.60 (1.45)** 9.39 (1.30)**
5.96 (0.75)*** 6.23 (0.73)***
aO2: arterial oxygen pressure; PaCO2: arterial carbon dioxide
e); ***Po0:001 (compared to baseline).
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M.L. Duiverman et al.621999)). In 1 other patient an attempt was made to
switch to NIPPV, unsuccessful due to anxiety. The
other 12 patients stayed on TIPPV. Half of them
died before 1986 when NIPPV was not available yet
at our hospital. In the other half, because the
patients had no complaints about the TIPPV, the
decision was made not to change a successful
treatment.
NIPPV
Seventy-eight patients received NIPPV (46 IK
patients, 18 PP patients, 14 M patients). Thirt-four
patients received NIPPV for at least 5 years (48.6%).
NIPPV improved pulmonary function and ABG after
9 months compared to baseline, and the improve-
ment in arterial blood gases was still evident after 5
years NIPPV (Table 2).
Only 1 IK patient switched from NIPPV to TIPPV
after 25 months because NIPPV could not give a
satisfactory relief of his clinical condition.
Volume or pressure support
Of the 78 patients on NIPPV, 27 patients received
volume-controlled ventilation (11 IK patients, 12 PP
patients, 4 M patients), 17 patients pressure-
controlled ventilation (11 IK patients, 2 PP pa-
tients, 4 M patients), and 28 patients BilevelPAP (21
IK patients, 4 PP patients, 3 M patients). Data
regarding the type of NIPPV were lost in 6 patients
and these patients were excluded from the
analyses.
Changes in home mechanical ventilatory support
modes are shown in Fig. 3. The first patients who0%
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Figure 3 Changes in ventilatory support mode of NIPPV f
Groningen.received NIPPV were instituted in 1989. In the first
years mostly volume-controlled ventilation was
available. As a relatively large percentage of the
patients instituted on NIPPV in the first years were
diagnosed with PP syndrome, most of these
patients were instituted on volume-controlled
ventilation. These days, there is an almost equal
proportion of volume-controlled and pressure-con-
trolled ventilation in our hospital.
The effects on pulmonary function and gas
exchange are presented in Table 3. Both
volume and pressure-controlled ventilation im-
proved pulmonary function and arterial blood gas
tensions.
Daily ventilator use
All the patients used their ventilator during the
night. At baseline, several patients used the
ventilator during the day as well (10 patients on
NIPPV (13%), 7 patients on TIPPV (44%) and 3
patients on NPV (16%)).
After 112 years, next to overnight use, significantly
more patients on NIPPV used their ventilator during
the day (34% (Po0:05)). In the TIPPV ventilated
patients (36%), and in the NPV ventilated patients
(27%) the degree of daytime use did not change
significantly.Discussion
The present study illustrates that both invasive
and non-invasive HMV are effective in terms of1997 1999 2001 2003 2005
year
ressure
olume
rom 1989 until 2005 in the University Medical Center
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Table 3 Changes in pulmonary function and
arterial blood gases in patients ventilated by NIPPV
by means of the volume-controlled mode or
pressure-controlled mode.
Baseline 9 months
Volume-cycled (n ¼ 27)
FEV1 0.59 (0.16) 0.73 (0.29)*
VC 1.00 (0.47) 1.09 (0.51)
PaO2 8.67 (1.96) 9.12 (1.22)
PaCO2 7.43 (1.49) 6.06 (0.94)**
Pressure-cycled (n ¼ 45)
FEV1 0.88 (0.26)*** 0.95 (0.26)*
VC 1.27 (0.47)y 1.39 (0.50)**
PaO2 7.83 (2.07) 9.53 (1.41)**
PaCO2 7.38 (1.31) 5.89 (0.44)**
Values are expressed as mean (SD).
Note: VC: vital capacity; FEV1: forced expiratory volume
in 1 s; PaO2: arterial oxygen pressure; PaCO2: arterial
carbon dioxide pressure.
*Po0:05 (compared to baseline); **Po0:001 (compared to
baseline); ***Po0:001 (pressure vs. volume-controlled);
yPo0:05 (pressure vs. volume-controlled).
HMV support in patients with restrictive ventilatory disorders 63short-term and long-term improvement of pulmon-
ary function and arterial blood gas tensions in
patients with kyphoscoliosis, PP syndrome, or a
miscellaneous restrictive ventilatory disorder.
Furthermore, the study demonstrates that vo-
lume-controlled ventilation and pressure-con-
trolled ventilation are equally effective in
improving pulmonary function and arterial blood
gas tensions in patients with restrictive ventilatory
disorders.
In this study, we selected the patients with
restrictive ventilatory disorders to analyze the
effects of HMV. Last years, the number of patients
on HMV in the area covered by the department of
HMV of the University Medical Center Groningen has
increased. These data agree with data from
Sweden.31 This increase in prevalence is mainly
due to an increase in the number of patients with
neuromuscular disorders, such as ALS, and patients
with OSAS/OHS that were instituted on HMV.
However, because the restrictive ventilatory dis-
order group has remained relatively constant over
several years now, we have been able to build up
long-term experience with HMV in a large number
of patients.
The IK and the PP patients showed survival rates
of 84% and 93% after 5 years, respectively. These
survival rates are comparable to previous studies in
these patients.16–18 The M group showed a sig-
nificantly worse survival rate of 62% after 5 years
compared to the IK and PP patients. The worse
survival rate of the M patients can partly beexplained by the older age at the start of HMV in
these patients compared to the IK and PP patients.
Furthermore, it is important to note that the M
patients were mainly patients who experienced
tuberculosis and therefore had an underlying
intrinsic lung disease.32–35 In the study of Jackson
et al.6 patients who underwent a thoracoplasty had
a 5-year survival rate of 64%, which is comparable
to the survival of our M group.
Two patients in our M group suffered from
bronchiectasis. Although it has been shown that
patients with bronchiectasis have very low survival
rates,17,18 the three bronchiectasis patients of the
M group in our study had a moderate survival rate.
One patient who initiated cuirass at age 47 died
after 16 years of ventilatory support, the other
patient who initiated NIPPV at age 70 died after 9
years ventilatory support. The long survival of
these patients tells us that not all patients with
bronchiestasis are bad candidates for chronic
ventilatory support.NPV
Several studies have shown benefits from long-term
home NPV in patients with restrictive ventilatory
disorders.4–7 However, direct comparisons between
NPV and NIPPV are rare. Baydur et al. described the
outcomes of 79 patients receiving home ventilation
by NPV or NIPPV. They found that in 25 patients
with poliomyelitis VC and PaCO2 did not change
significantly on body ventilation (tank or shell) and
that NIPPV resulted in better outcomes in terms of
a decreased number of tracheotomies and a better
survival rate compared to NPV.24 We did find an
improvement of pulmonary function and ABG and,
although in the IK group there seemed to be a
survival benefit for the NIPPV ventilated patients,
we did not find a difference in overall survival rates
between the patients on NPV and those on NIPPV.
Furthermore, in our study only 2 patients on NPV
switched to TIPPV (10%) compared to 56% in the
study of Baydur.
However, patient characteristics and diagnoses
of the patients were different in the study of
Baydur and in our study. Secondly, as more than half
of Baydur’s patients were instituted on ventilatory
support during the primary phase of poliomyelitis at
a young age, the duration of NPV in the study of
Baydur (mean 24 years) was far longer than in our
study (mean 12.5 years). This might explain the
high number of tracheostomies in the study of
Baydur, compared to our study.
On the basis of outcomes in terms of physical
effects, no conclusion can be drawn about superiority
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M.L. Duiverman et al.64of NPV or NIPPV. However, because of the difficult
and cumbersome use of NPV, nowadays NIPPV tends
to be the first choice. Our study again shows that
NPV can be effective in restrictive ventilatory
disorders. This supports the idea that NPV remains
a second choice to be used in patients whom, for
technical or other reasons, cannot be offered
NIPPV.36TIPPV
In our study 20 patients started with TIPPV. Most of
our patients on TIPPV required this type of
ventilation because of acute on chronic respiratory
failure which could not be controlled by NIPPV or
because of uncontrollable sputum clearance pro-
blems. However, with the availability of a variety of
nasal and mouth interfaces, coughing techniques
and machines, it became increasingly possible to
use NIPPV instead of TIPPV, even in acute situa-
tions. In the period from 1997–2005, only 1 PP
patient eventually required chronic TIPPV, because
of deteriorating blood gasses and a deteriorating
clinical condition on NIPPV.
Three of the patients on TIPPV changed success-
fully to NIPPV. In two other patients, severe sputum
clearance problems and anxiety for not being
adequately ventilated at night hindered a success-
ful switch to NIPPV. The patients required TIPPV in
the acute situation but were in a stable condition at
the time of the switch. In the future, we should try
to switch more tracheostomal ventilated patients
to NIPPV when their condition has stabilized, as
NIPPV has many advantages over TIPPV. Never-
theless, as TIPPV has shown a high degree of
effectiveness in patients with a restrictive ventila-
tory disorder, it still remains a good alternative for
some patients.
Our results agree with the study of Zaccaria et al.
who found that in patients with respiratory
insufficiency who were treated by TIPPV arterial
blood gasses improved to a same degree than in
patients treated by NIPPV. Furthermore, they found
that these effects were still evident after 1 year of
ventilation.10NIPPV
Several studies have shown that NIPPV is effective
in patients with restrictive ventilatory disor-
ders.11–28 In our study, NIPPV improved ABG and
pulmonary function, and these positive effects
were significant even after of 5 years ventilatory
support. Only 1 patient with chronic hypoxia,
pulmonary hypertension, and heart failure changedto TIPPV after 25 months of NIPPV because severe
air leakage hindered an adequate oxygenation.
Several potential mechanisms are postulated to
explain the effects of NIPPV. It may improve the
mechanical properties of the thorax, it may ‘‘rest’’
the respiratory muscles, and it may improve
respiratory drive.31,37 We can only suggest that, in
our patients, NIPPV worked through improving the
mechanical properties of the thorax (as we did find
a small improvement in VC and FEV1), probably in
combination with the other mechanism mentioned
above. However, we did not measure respiratory
muscle strength, respiratory muscle activity, or CO2
sensitivity.
According to the Conference Consensus of 1999,
daytime hypercapnia in combination with symp-
toms of shortness of breath on exertion, tiredness,
sleepiness, and ankle swelling is the primary
indication for starting NIPPV.38 Furthermore, we
found that the success of HMV seems to be linked to
the clinical condition of patients at the time they
were instituted. The patients who were instituted
acutely had worse baseline arterial blood gases and
pulmonary function, and seemed to have a worse
survival rate on HMV than the patients instituted
non-emergently. Furthermore, more patients suf-
fering from acute respiratory failure had to be
trachestomized. Therefore, it seems better to
initiate ventilator support before patients deterio-
rate into acute respiratory failure. Recently it has
been suggested that starting NIPPV at the stage of
nocturnal hypoventilation before daytime hyper-
capnia ensues can prevent ventilatory decompen-
sation,39 which suggests that it is a good policy to
initiate NIPPV even earlier in the course of the
disease, maybe even before daytime hypercapnia
develops.
In summary, NPV, TIPPV, and NIPPV have a
positive effect on pulmonary function and arterial
blood gas tensions both at short-term and long-
term. If patients receive NIPPV the mode of
ventilation did not show different effects on
pulmonary function and ABG. Patients with IK and
PP syndrome showed a significantly better survival
rate compared to the M group. As the underlying
disorder determines survival and probably the
course of the disease, we think it is important to
assess the effects of HMV in patients with different
disorders separately.References
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